The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Significance of zoledronic acid on survival in patients with bone metastases from renal cell carcinoma.
Yasuhisa Fujii
No relevant relationships to disclose
Yosuke Yasuda
No relevant relationships to disclose
Takeshi Yuasa
No relevant relationships to disclose
Gen Sukegawa
No relevant relationships to disclose
Shinichi Kitsukawa
No relevant relationships to disclose
Shinji Urakami
No relevant relationships to disclose
Shinya Yamamoto
No relevant relationships to disclose
Junji Yonese
No relevant relationships to disclose
Shunji Takahashi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Iwao Fukui
No relevant relationships to disclose